Prediction: Lilly Will Trade at $1,200 by Year-End
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Index movements reflect changes in component stock prices, earnings, macro data, and capital flows. This overview highlights the main drivers behind daily swings.
18,176 articlesInvestors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
A CNBC analyst contends the FedEx selloff reflects misinterpretation of the income statement, not a collapse in deman...
A veteran CIO warns that even stellar AI earnings may not keep momentum, suggesting the market is testing whether thi...
Johnson Johnson walking away from a GLP-1 obesity obsession signals a shift to a diversified, potentially more resili...
Credo Technology rides a surge in AI infrastructure demand, but the path to $500 by 2030 hinges on durable revenue gr...
IBM is attracting fresh investor attention as its AI infrastructure strategy gains traction. Arvind Krishna’s reshape...
Netflix is set to release its Q2 earnings after the bell tonight, with investors watching ad revenue growth, content ...
Tesla faces a pivotal Q2 print as shares struggle in 2026. While deliveries rose, investors will be watching margins,...
When a top executive sells shares as a company commits billions to its hubs, it can spark questions. This article bre...
As travel rebounds, premium demand is reshaping cruise stock dashboards. This deep dive explains why norwegian cruise...
Institutional moves can reveal where smart money sees durable cash flow. Learn why ancora advisors opens $148 million...
Moderna and Ross Stores surged midweek on distinct catalysts: a patent settlement clearing a key overhang for Moderna...